Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 2, 2011Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics
Tokyo, Japan, December 2, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that the company's U.S. research subsidiary H3 Biomedicine...
-
Oct 25, 2011Funding made possible through the support of Eisai Inc.
Woodcliff Lake, NJ, October 25, 2011 - The Breast Cancer Research Foundation (BCRF) announced today that it has awarded a research grant to Daniel F. Hayes, MD, Director of the Breast Oncology...
-
Sep 23, 2011
Lugano, Switzerland and Woodcliff Lake, NJ, USA Sept. 23, 2011 - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program...
-
Jul 19, 2011
Tokyo, Japan, July 19, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today announced the launch of its novel anticancer agent Halaven in Japan for the...
-
Jul 13, 2011
Woodcliff Lake, NJ, July 13, 2011 - Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking...